The randomized, double‐blind, cardiovascular outcomes trials LEADER (NCT01179048)
and SUSTAIN 6 (NCT01720446) showed cardiovascular risk reduction in patients with type …

Aim To evaluate the cardiovascular (CV) efficacy of liraglutide and semaglutide in patients
with type 2 diabetes (T2D) and peripheral artery disease (PAD). Materials and Methods …

CORRESPONDENCE years), and more patients were male (68.8% versus 67.9%), were
current or previous smokers (67.1% versus 60.1%), had an estimated glomerular filtration …

Background: The glucagon-like peptide-1 analog liraglutide reduced cardiovascular events
and mortality in patients with type 2 diabetes mellitus in the LEADER trial (Liraglutide and …

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) reduce cardiovascular (CV) events
among patients with type 2 diabetes and high CV risk. Because consensus professional …

Hyperglycemia is the major risk factor for microvascular complications in patients with type 2
diabetes (T2D). However, cardiovascular disease (CVD) is the principal cause of death, and …

An important challenge in the management of patients with type 2 diabetes is cardiovascular
disease (CVD) prevention. While it is well established that intensive glycemic control …

Background Impaired coronary microcirculation is associated with a poor prognosis in
patients with type 2 diabetes. In the absence of stenosis of major coronary arteries, coronary …

Cardiovascular risk reduction with liraglutide and semaglutide in patients with type 2
diabetes was demonstrated in the LEADER (ClinicalTrials. gov: NCT01179048) and …

This commentary analyzes the Liraglutide Effect and Action in Diabetes: Evaluation of
Cardiovascular Outcome Results (LEADER) trial, which has reported the cardiovascular …